Copertina

Editorial: Prevention of Upper GI Bleeding in Users of Anti‐Thrombotic Drugs—P‐ CABs Versus PPIs

Fuente: Wiley Open Access

Salvato in:

Dettagli Bibliografici
Autore principale:	Ali S. Taha
Natura:	Artículo Open Access
Pubblicazione:	Wiley 2026
Soggetti:	Alimentary Pharmacology & Therapeutics
Accesso online:	Acceder al recurso
Tags:	Aggiungi Tag Nessun Tag, puoi essere il primo ad aggiungerne!!

Documenti analoghi

Editorial: Prevention of Upper GI Bleeding in Users of Anti‐Thrombotic Drugs—P‐ CABs Versus PPIs . Authors' Reply
di: Min Joo Yoon, et al.
Pubblicazione: (2026)

P‐ CAB vs. PPI for Upper Gastrointestinal Bleeding Prevention in Patients With Atherothrombotic Disease on Antithrombotic Therapy: A CDM Cohort Study
di: Min Joo Yoon, et al.
Pubblicazione: (2026)

Letter: Interpreting Apparent P‐ CAB Superiority for Antithrombotic‐Associated Upper Gastrointestinal Bleeding
di: Xiaoqing Yang, et al.
Pubblicazione: (2026)

Editorial: Variceal Bleeding in Patients Receiving Atezolizumab–Bevacizumab for Hepatocellular Carcinoma—Don't Ignore the Risk Factors! Authors' Reply
di: Jonggi Choi
Pubblicazione: (2025)

Editorial: Can We Prevent Inflammatory Bowel Disease?
di: Agnes Hiu Yan Ho, et al.
Pubblicazione: (2025)

Antiplatelet Resumption Timing in Post‐Percutaneous Coronary Intervention Gastrointestinal Bleeding
di: Darrick K. Li, et al.
Pubblicazione: (2026)

Risk of Variceal Bleeding in Patients Receiving Atezolizumab–Bevacizumab Treatment for Hepatocellular Carcinoma
di: Kanghee Park, et al.
Pubblicazione: (2025)

Editorial: Gene Silencing Therapy for a New Era of Pancreatitis Prevention
di: Maxim S. Petrov
Pubblicazione: (2026)

Editorial: Can We Prevent Inflammatory Bowel Disease? Authors' Reply
di: Fai Fai Ho, et al.
Pubblicazione: (2025)

Letter: The Risk and Outcomes of Gastrointestinal Bleeding in Patients Using Warfarin or Direct Oral Anticoagulants
di: Jiaqi Shen, et al.
Pubblicazione: (2026)

Letter: Post‐Banding Ulcer Bleeding Is More Common With Urgent EBL and Renal Dysfunction
di: Jurij Maurer, et al.
Pubblicazione: (2026)

Editorial: Shingles Risk in IBD —More Evidence to Support Routine Preventive Vaccination?
di: Keith Bodger
Pubblicazione: (2025)

Research Communication: The Risk and Outcomes of Gastrointestinal Bleeding in Patients Using Warfarin or Direct Oral Anticoagulants
di: Lauren Holtslander, et al.
Pubblicazione: (2025)

Editorial: Is There a Role for Therapeutic Drug Monitoring of Subcutaneous Infliximab in Patients With Inflammatory Bowel Disease?
di: Konstantinos Papamichael, et al.
Pubblicazione: (2024)

Letter: Incidence and Predictors of Major Gastrointestinal Bleeding in Patients on Aspirin, Low‐Dose Rivaroxaban or the Combination: Secondary Analysis of the COMPASS Randomised Controlled Trial
di: Yu Yang, et al.
Pubblicazione: (2024)

Head‐to‐Head Comparison Between Phosphatidylethanol Versus Indirect Alcohol Biomarkers for Diagnosis of MetALD Versus MASLD: A Prospective Study
di: Federica Tavaglione, et al.
Pubblicazione: (2025)

Editorial: Tenofovir Alafenamide Versus Entecavir for Hepatitis B Surface Antigen Decline–A Step Toward Functional Cure or a Marginal Margin?
di: Yao‐Chun Hsu, et al.
Pubblicazione: (2026)

Letter on ‘Head‐to‐Head Comparison Between Phosphatidylethanol Versus Indirect Alcohol Biomarkers for Diagnosis of MetALD Versus MASLD: A Prospective Study’
di: Muhammad Abubakr, et al.
Pubblicazione: (2025)

Letter: Incidence and Predictors of Major Gastrointestinal Bleeding in Patients on Aspirin, Low‐Dose Rivaroxaban or the Combination: Secondary Analysis of the COMPASS Randomised Controlled Trial. Authors' Reply
di: Nauzer Forbes, et al.
Pubblicazione: (2024)

Editorial: Shooting in the Dark—The Problem With Empiric Antispasmodics for Abdominal Pain in Inflammatory Bowel Disease
di: Jane Lim, et al.
Pubblicazione: (2025)

Letter on ‘Post‐TIPS Overt Hepatic Encephalopathy Increases Long‐Term but Not Short‐Term Mortality in Cirrhotic Patients With Variceal Bleeding: A Large‐Scale, Multicentre Real‐World’
di: Silvia Nardelli, et al.
Pubblicazione: (2025)

Post‐TIPS Overt Hepatic Encephalopathy Increases Long‐Term but Not Short‐Term Mortality in Cirrhotic Patients With Variceal Bleeding: A Large‐Scale, Multicenter Real‐World Study
di: Yi Xiang, et al.
Pubblicazione: (2025)

Review article: Prevention of inflammatory bowel disease—The path forward
di: Sérgio Bronze, et al.
Pubblicazione: (2024)

Letter: Rifaximin Versus Low FODMAP Diet in IBS : What the Primary Endpoint Does Not Tell Us
di: Luisa Bertin, et al.
Pubblicazione: (2026)

Factors Associated With Underutilization of Antiviral Therapy in Preventing Hepatitis B Virus‐Related Hepatocellular Carcinoma
di: Jia‐Ling Wu, et al.
Pubblicazione: (2025)

Correction to ‘Risk of Hepatocellular Cancer in U.S. Patients With Compensated Cirrhosis Treated With Direct‐Acting Antivirals Versus Interferon’
Pubblicazione: (2025)

Editorial on ‘Early HBcrAg and Anti‐ HBc Levels Identify Patients at High Risk for Severe Flares After Nucleos(t)ide Analogue Cessation: A Pooled Analysis of Two Clinical Trials’
di: Ming Chao Tsai, et al.
Pubblicazione: (2025)

Clinical Trial: Semaglutide Versus Placebo in NIT ‐Assessed MASH —A Multicenter Randomised Placebo‐Controlled Trial ( SAMARA )
di: Veeral Ajmera, et al.
Pubblicazione: (2026)

Long‐Term Outcomes of an Infliximab‐First Versus Vedolizumab‐First Treatment Strategy in Biologic‐Naïve Patients With Ulcerative Colitis
di: Austin Haynesworth, et al.
Pubblicazione: (2024)

Clinical Trial: Immunogenicity of Double‐Dose Versus Standard‐Dose of Hepatitis B Virus Vaccine in Inflammatory Bowel Disease
di: Anupam Kumar Singh, et al.
Pubblicazione: (2025)

Letter: Optimising Prevention of Adverse Events and Antiviral Prophylaxis for HBV ‐Infected HCC Patients Undergoing Immunotherapy
di: Jialing Wang, et al.
Pubblicazione: (2025)

Review Article: Drug Approval for Gastroparesis—Suggestions for Improving the Process for Positive Results
di: Michael Camilleri, et al.
Pubblicazione: (2026)

Clinical Trial: Safety and Efficacy of a Novel Oesophageal Delivery System for Topical Corticosteroids Versus Placebo in the Treatment of Eosinophilic Oesophagitis
di: Alfredo J. Lucendo, et al.
Pubblicazione: (2024)

Upper limit of normal ALT levels in health and metabolic diseases: Pooled analysis of 423,355 individuals with bootstrap modelling
di: Eunice X. Tan, et al.
Pubblicazione: (2024)

Letter: Drug‐Induced Autoimmune‐Like Hepatitis—A Trigger on the Disease Spectrum. Authors' Reply
di: Pinelopi Arvaniti, et al.
Pubblicazione: (2025)

Review Article: Drug‐Induced Liver Injury Associated With Antibody‐Based Therapies in Haematologic Malignancies
di: Mengmeng Lin, et al.
Pubblicazione: (2025)

Clinical Trial: Long Versus Short Tapering of Steroids in Steroid Responsive Moderate to Severely Active Ulcerative Colitis—A Randomised Controlled Trial
di: Ankit Kumar, et al.
Pubblicazione: (2026)

Letter on ‘Inherited Genetic Risk of Liver Fibrosis in Lean Versus Nonlean Metabolic Dysfunction‐Associated Steatotic Liver Disease ( MASLD )’; Authors’ reply
di: Kaleb Tesfai, et al.
Pubblicazione: (2026)

Clinical Trial: Dose‐Finding Study of Linaprazan Glurate, A Novel Potassium‐Competitive Acid Blocker, Versus Lansoprazole for the Treatment of Erosive Oesophagitis
di: Prateek Sharma, et al.
Pubblicazione: (2025)

Letter: Using Anti‐ HBs Titres to Tailor HBV Reactivation Monitoring in Patients With Solid Tumours
di: Tsutomu Nishida, et al.
Pubblicazione: (2026)